Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898250 | 0.86 | RAB9A (0.52) | TSHRKMT2AALDH1A1HSD17B10RAB9A | |
| SCHEMBL12898281 | 0.84 | NLRP3 (0.43) | TSHRALDH1A1HSD17B10RAB9ASMN1; SMN2 | |
| SCHEMBL12898272 | 0.83 | TSHR (0.40) | USP2TSHRKMT2AHSD17B10RAB9A | |
| SCHEMBL12898263 | 0.82 | MAPK1 (0.42) | KMT2AALDH1A1RAB9ASMN1; SMN2APOBEC3A | |
| SCHEMBL12898282 | 0.80 | NPC1 (0.53) | TSHRKMT2ARAB9ASMN1; SMN2HTT | |
| SCHEMBL12898285 | 0.79 | NPSR1 (0.55) | KMT2AALDH1A1RAB9ASMN1; SMN2HTT | |
| SCHEMBL12898274 | 0.78 | HPGD (0.49) | TSHRKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12898264 | 0.77 | HPGD (0.51) | TSHRKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12898271 | 0.77 | TSHR (0.49) | TSHRKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12898269 | 0.77 | TRPV1 (0.44) | KMT2ARAB9ASMN1; SMN2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | USP2 4264/4885TSHR 4679/4885KMT2A 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.